Yaoxing Huang
Co-Founder
RenBio
RenBio utilizes its proprietary MYO Technology™ to deliver therapeutic-encoding DNA bioblueprints via intramuscular injection, enabling the body to produce specific antibodies and therapeutic proteins. This approach addresses the challenges of traditional antibody administration by enhancing efficacy, durability, and cost-effectiveness in the treatment of cancer and inflammatory diseases.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$28MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
David Ho
Co-Founder
Product
Problem
Traditional antibody and protein therapies face challenges related to administration, efficacy, durability, and high production costs, which limit their widespread use and accessibility. Current delivery methods often require frequent clinic visits and may not elicit a sustained therapeutic effect.
Solution
RenBio is developing a DNA-based therapeutic platform, MYO Technology™, that enables the body to produce its own antibodies and therapeutic proteins. This is achieved by delivering therapeutic-encoding DNA "bioblueprints" via intramuscular injection, which are then decoded by muscle cells to synthesize the desired therapeutics directly within the patient's body. This approach aims to improve upon existing antibody therapies by enhancing efficacy, durability, and cost-effectiveness, while also simplifying the administration process. The platform has the potential to address a wide range of diseases, including cancer and infectious diseases.
Target Audience
The primary target audience includes patients with cancer, inflammatory diseases, and infectious diseases, as well as healthcare providers seeking more effective and accessible therapeutic options.
Features
- MYO Technology™: A platform for delivering therapeutic-encoding DNA via intramuscular injection.
- In-vivo antibody and protein production: Enables the patient's own muscle cells to produce therapeutic proteins.
- Potential for improved efficacy and durability compared to traditional antibody therapies.
- Simplified administration: Intramuscular injection reduces the need for frequent infusions.
- Applicability to a range of diseases: Platform can be adapted to produce various antibodies and therapeutic proteins.